STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 192170

TO: Marcela Cordero Garcia **Location: Rem/3a30/3c18** **Art Unit: 1654** **Tuesday, June 06, 2006** **Case Serial Number: 10/796158**	**From: Toby Port** **Location: Biotech-Chem Library** **REM-1A59** **Phone: (571)272-2523** **toby.port@uspto.gov**

Search Notes

Dear Examiner Cordero Garcia,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Toby Port
Technical Information Specialist
STIC Biotech/Chem Library
(571)272-2523

Sorry for the delay. Mea Culpa!

Toby

```
=> file reg; d que l1
FILE 'REGISTRY' ENTERED AT 16:04:18 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 JUN 2006  HIGHEST RN 886840-90-0
DICTIONARY FILE UPDATES:   5 JUN 2006  HIGHEST RN 886840-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L1          6 SEA FILE=REGISTRY ABB=ON  PLU=ON YCYYCFWKTCT|CYYYCFWKTCT|YYCYC
              FWKTCT/SQSP


=> d l1 rn cn sql kwic nte 1-6

L1   ANSWER 1 OF 6  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   760191-73-9  REGISTRY
CN   L-Threonine, L-tyrosyl-L-tyrosyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-
     phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl- (9CI)  (CA INDEX
     NAME)
OTHER NAMES:
CN   7: PN: WO2004081031 SEQID: 7 unclaimed sequence
SQL  11

SEQ      1 YYCYCFWKTC T
           ========== =
HITS AT:   1-11
```

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L1 ANSWER 2 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 760191-72-8 REGISTRY
CN L-Threonine, L-cysteinyl-L-tyrosyl-L-tyrosyl-L-tyrosyl-L-cysteinyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO2004081031 SEQID: 6 unclaimed sequence
SQL 11

SEQ 1 CYYYCFWKTC T
========== =
HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L1 ANSWER 3 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 760191-71-7 REGISTRY
CN L-Threonine, L-tyrosyl-L-cysteinyl-L-tyrosyl-L-tyrosyl-L-cysteinyl-L-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: WO2004081031 SEQID: 5 unclaimed sequence
SQL 11

SEQ 1 YCYYCFWKTC T
========== =
HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L1 ANSWER 4 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 757951-73-8 REGISTRY
CN L-Threonine, D-tyrosyl-D-tyrosyl-D-cysteinyl-D-tyrosyl-L-cysteinyl-D-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (5→10)-disulfide (9CI) (CA INDEX NAME)
SQL 11

SEQ 1 YYCYCFWKTC T
========== =
HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK
NTE

type	------ location ------		description
bridge	Cys-5	- Cys-10	disulfide bridge

L1 ANSWER 5 OF 6 REGISTRY COPYRIGHT 2006 ACS on STN
RN 757951-72-7 REGISTRY
CN L-Threonine, D-cysteinyl-D-tyrosyl-D-tyrosyl-D-tyrosyl-L-cysteinyl-D-phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic (5→10)-disulfide (9CI) (CA INDEX NAME)
SQL 11

SEQ 1 CYYYCFWKTC T

```
          ========== =
HITS AT:   1-11

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
NTE
-----------------------------------------------------------------------
 type            ------ location ------         description
-----------------------------------------------------------------------
bridge           Cys-5       - Cys-10      disulfide bridge
-----------------------------------------------------------------------

L1   ANSWER 6 OF 6  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   757951-71-6  REGISTRY
CN   L-Threonine, D-tyrosyl-D-cysteinyl-D-tyrosyl-D-tyrosyl-L-cysteinyl-D-
     phenylalanyl-L-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-, cyclic
     (5→10)-disulfide (9CI)  (CA INDEX NAME)
SQL  11

SEQ      1 YCYYCFWKTC T
          ========== =
HITS AT:   1-11

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
NTE
-----------------------------------------------------------------------
 type            ------ location ------         description
-----------------------------------------------------------------------
bridge           Cys-5       - Cys-10      disulfide bridge
-----------------------------------------------------------------------


=> file caplus; d que l2
FILE 'CAPLUS' ENTERED AT 16:07:50 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Jun 2006  VOL 144 ISS 24
FILE LAST UPDATED: 5 Jun 2006  (20060605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html


L1            6 SEA FILE=REGISTRY ABB=ON  PLU=ON  YCYYCFWKTCT|CYYYCFWKTCT|YYCYC
                FWKTCT/SQSP
L2            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L1
```

=> d ibib ed ab hitrn

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:780722 CAPLUS
DOCUMENT NUMBER: 141:271609
TITLE: Thiol-mediated drug attachment to targeting peptides
INVENTOR(S): Braslawsky, Gary R.; Chinn, Paul
PATENT ASSIGNEE(S): Biogen Idec Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081031	A2	20040923	WO 2004-US7143	20040310
WO 2004081031	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220104	A1	20040923	AU 2004-220104	20040310
CA 2518406	AA	20040923	CA 2004-2518406	20040310
US 2005118099	A1	20050602	US 2004-796158	20040310
EP 1610805	A2	20060104	EP 2004-719192	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-452928P P 20030310
WO 2004-US7143 A 20040310

ED Entered STN: 24 Sep 2004
AB The invention discloses compns. and methods for thiol-specific attachment of therapeutic and diagnostic agents to somatostatin and other targeting peptides. Compns. of the invention include somatostatin analogs AB (A = cysteine or cysteine-containing peptide suitable for binding to drug or chelator via thiol linkage; B = somatostatin peptide or fragment that binds to somatostatin receptor).
IT **757951-71-6D**, C-terminus amide or alc. **757951-72-7D**, C-terminus amide or alc. **757951-73-8D**, C-terminus amide or alc.
RL: DGN (Diagnostic use); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thiol-mediated drug attachment to targeting peptides)
IT **760191-71-7 760191-72-8 760191-73-9**
RL: PRP (Properties)
(unclaimed sequence; thiol-mediated drug attachment to targeting peptides)

=> => file caplus; d que l5
FILE 'CAPLUS' ENTERED AT 16:26:43 ON 06 JUN 2006

FILE COVERS 1907 - 6 Jun 2006 VOL 144 ISS 24
FILE LAST UPDATED: 5 Jun 2006 (20060605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
L3          41 SEA FILE=CAPLUS ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4          21 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHINN P?/AU
L5           5 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDES/CW
```

```
=> file medline; d que l8
FILE 'MEDLINE' ENTERED AT 16:27:01 ON 06 JUN 2006

 FILE LAST UPDATED: 3 JUN 2006 (20060603/UP). FILE COVERS 1950 TO DATE.

 On December 11, 2005, the 2006 MeSH terms were loaded.

 The MEDLINE reload for 2006 is now (26 Feb.) available. For details
 on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
 See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

 OLDMEDLINE is covered back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2006 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L3            41 SEA FILE=CAPLUS ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4            21 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHINN P?/AU
L8             3 SEA FILE=MEDLINE ABB=ON PLU=ON  (L3 OR L4) AND PEPTIDE?


=> file embase; d que l12
FILE 'EMBASE' ENTERED AT 16:27:08 ON 06 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

 FILE COVERS 1974 TO 6 Jun 2006 (20060606/ED)

 EMBASE has been reloaded. Enter HELP RLOAD for details.

 EMBASE is now updated daily. SDI frequency remains weekly (default)
 and biweekly.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


L3            41 SEA FILE=CAPLUS ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4            21 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHINN P?/AU
L12            2 SEA FILE=EMBASE ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?


=> file biosis; d que l13
FILE 'BIOSIS' ENTERED AT 16:27:15 ON 06 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 May 2006 (20060531/ED)
```

```
L3            41 SEA FILE=CAPLUS ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4            21 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHINN P?/AU
L13            2 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?

=> file wpix; d que l14
FILE 'WPIX' ENTERED AT 16:27:21 ON 06 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED:          2 JUN 2006      <20060602/UP>
MOST RECENT DERWENT UPDATE:     200635        <200635/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<


L3            41 SEA FILE=CAPLUS ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4            21 SEA FILE=CAPLUS ABB=ON  PLU=ON  CHINN P?/AU
L14            7 SEA FILE=WPIX ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?


=> dup rem l8 l5 l12 l13 l14
FILE 'MEDLINE' ENTERED AT 16:27:36 ON 06 JUN 2006

FILE 'CAPLUS' ENTERED AT 16:27:36 ON 06 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 16:27:36 ON 06 JUN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:27:36 ON 06 JUN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'WPIX' ENTERED AT 16:27:36 ON 06 JUN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
PROCESSING COMPLETED FOR L8
PROCESSING COMPLETED FOR L5
PROCESSING COMPLETED FOR L12
PROCESSING COMPLETED FOR L13
PROCESSING COMPLETED FOR L14
L15           12 DUP REM L8 L5 L12 L13 L14 (7 DUPLICATES REMOVED)
                ANSWERS '1-3' FROM FILE MEDLINE
                ANSWERS '4-8' FROM FILE CAPLUS
                ANSWERS '9-12' FROM FILE WPIX

=> d ibib ed ab l15 1-8; d ibib ab abex l15 9-12
```

L15 ANSWER 1 OF 12 MEDLINE on STN DUPLICATE 3
ACCESSION NUMBER: 93294279 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8515057
TITLE: Identification of functional domains in murine granulocyte-macrophage colony-stimulating factor using monoclonal antibodies to synthetic **peptides.**
AUTHOR: Greenfield R S; **Braslawsky G R**; Kadow K F; Spitalny G L; Chace D; Bull C O; Bursuker I
CORPORATE SOURCE: Bristol-Myers Squibb Co., Pharmaceutical Research Institute, Wallingford, CT 06492.
SOURCE: Journal of immunology (Baltimore, Md. : 1950), (1993 Jun 15) Vol. 150, No. 12, pp. 5241-51.
Journal code: 2985117R. ISSN: 0022-1767.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 199307
ENTRY DATE: Entered STN: 6 Aug 1993
Last Updated on STN: 6 Aug 1993
Entered Medline: 20 Jul 1993
ED Entered STN: 6 Aug 1993
Last Updated on STN: 6 Aug 1993
Entered Medline: 20 Jul 1993
AB Granulocyte-macrophage (GM)-CSF is an important hematopoietic cytokine that regulates proliferation and differentiation of macrophages, neutrophils, and eosinophils. In this study, we generated mAb to five synthetic **peptides** that correspond to regions along the murine GM-CSF molecule. The ability of anti-**peptide** mAb to bind to and inhibit biologic activity of murine (m) GM-CSF was determined. mAb with the highest neutralization titers were derived from mice immunized with **peptide** II, which correspond to amino acids 27 to 38 of mGM-CSF. Immunochemical studies showed that **peptide** II specifically blocked binding of anti-**peptide** II mAb to GM-CSF. mAb to two other **peptides** in the N-terminal half corresponding to residues 7 to 17 and 47 to 58, respectively, of mGM-CSF also inhibited GM-CSF-dependent proliferation and differentiation of murine bone marrow precursors for macrophages and granulocytes. Anti-**peptide** mAb also inhibited growth of a murine hematopoietic cell line FDCP1 and a murine T cell line HT-2, which was shown to be dependent on GM-CSF for growth in vitro. Biologic activity of both natural and recombinant mGM-CSF was neutralized by anti-**peptide** mAb. These findings indicate that epitopes in the N-terminal region of mGM-CSF are important for biologic activity, and the epitope defined by **peptide** II (residues 27 to 38) lies within a particularly important functional domain of the mGM-CSF molecule.

L15 ANSWER 2 OF 12 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 94065479 MEDLINE
DOCUMENT NUMBER: PubMed ID: 8245704
TITLE: Granulocyte-macrophage colony-stimulating factor plays a role in the functional activity of mast cells.
AUTHOR: Meade R; Neddermann K M; Greenfield R S; **Braslawsky G**; Bursuker I
CORPORATE SOURCE: Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492-7660.
SOURCE: Journal of leukocyte biology, (1993 Dec) Vol. 54, No. 6, pp. 523-7.
Journal code: 8405628. ISSN: 0741-5400.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199401
ENTRY DATE: Entered STN: 1 Feb 1994
Last Updated on STN: 1 Feb 1994
Entered Medline: 6 Jan 1994

ED Entered STN: 1 Feb 1994
Last Updated on STN: 1 Feb 1994
Entered Medline: 6 Jan 1994

AB A **peptide** homologous to a region of murine granulocyte-macrophage colony-stimulating factor (mGM-CSF), P27-38, which was shown to be a GM-CSF antagonist, inhibited the function of serotonin release from murine mast cells. **Peptide** P27-38 inhibited immunoglobulin E (IgE)-mediated serotonin release in a dose-dependent manner when induced by either specific antigen or anti-IgE antibody. In contrast, non-receptor-mediated release of serotonin by agents such as compound 48/80 or the calcium ionophore A23187 were not affected by the GM-CSF antagonist. Similar effects were observed with GM-CSF-neutralizing antibodies. The inhibitory effect of P27-38 and the neutralizing antibodies on serotonin release could be reversed by the addition of exogenous GM-CSF to the stimulated mast cells, indicating that the inhibitory activity was probably due to an effect on endogenously produced GM-CSF. These findings suggest that GM-CSF produced by stimulated mast cells is involved in the regulation of their activity in an autocrine manner.

L15 ANSWER 3 OF 12 MEDLINE on STN
ACCESSION NUMBER: 85238871 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2409352
TITLE: Effect of a cyclic hexapeptide analog (L363,586) of somatostatin on the function of pancreas grafts in dogs.
AUTHOR: Liu T; Sutherland D E; **Chinn P L**; Najarian J S
SOURCE: The Journal of surgical research, (1985 Jul) Vol. 39, No. 1, pp. 39-45.
Journal code: 0376340. ISSN: 0022-4804.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198508
ENTRY DATE: Entered STN: 20 Mar 1990
Last Updated on STN: 6 Feb 1995
Entered Medline: 20 Aug 1985

ED Entered STN: 20 Mar 1990
Last Updated on STN: 6 Feb 1995
Entered Medline: 20 Aug 1985

AB Complications related to the exocrine secretions cause some pancreas grafts to fail in the early postoperative period. Somatostatin inhibits exocrine secretion, as well as insulin and glucagon release. L363,586 is a cyclic hexapeptide analog of somatostatin that is 50 to 100 times more potent than the native hormone in inhibiting islet hormone release. In a preliminary experiment in which permanent fistulas were created in two dogs, we demonstrated that L363,586 (0.3 micrograms/kg/60 min) results in a fourfold decrease in pancreatic exocrine secretion when measured for 210 min following a beef meal. In a separate experiment, five totally pancreatectomized dogs who received segmental pancreas autografts with pancreaticoductocystostomy 10 months previously had L363,586 (0.3 micrograms/kg/hr) administered by the Alzet osmotic pump subcutaneously

for 7 days. Mean (+/-SE) daily serum amylase activity (IU/dl) during the week before the implant was 78 +/- 3, during the week of infusion was 65 +/- 2 (P less than 0.001), and during the week afterward was 76 +/- 2. In a prospective experiment, 12 totally pancreatectomized dogs received segmental pancreas autografts with anastomosis of the graft vessels to the iliac vessels and of the pancreatic duct to the bladder. L363,586 was administered by osmotic pump for 7 days to seven dogs at a dose of 0.3 micrograms/kg/hr. Mean (+/-SE) daily serum amylase levels at 1, 2, and 3 weeks posttransplant were 223 +/- 17, 81 +/- 3, and 82 +/- 5 in the L363,586-treated dogs and 229 +/- 18, 108 +/- 5, and 90 +/- 5 in the five untreated dogs (P less than 0.001 at 2 weeks).(ABSTRACT TRUNCATED AT 250 WORDS)

L15 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:780722 CAPLUS
DOCUMENT NUMBER: 141:271609
TITLE: Thiol-mediated drug attachment to targeting peptides
INVENTOR(S): **Braslawsky, Gary R.; Chinn, Paul**
PATENT ASSIGNEE(S): Biogen Idec Inc., USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081031	A2	20040923	WO 2004-US7143	20040310
WO 2004081031	A3	20050310		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004220104	A1	20040923	AU 2004-220104	20040310
CA 2518406	AA	20040923	CA 2004-2518406	20040310
US 2005118099	A1	20050602	US 2004-796158	20040310
EP 1610805	A2	20060104	EP 2004-719192	20040310
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: US 2003-452928P P 20030310
WO 2004-US7143 A 20040310

ED Entered STN: 24 Sep 2004
AB The invention discloses compns. and methods for thiol-specific attachment of therapeutic and diagnostic agents to somatostatin and other targeting peptides. Compns. of the invention include somatostatin analogs AB (A = cysteine or cysteine-containing peptide suitable for binding to drug or chelator via thiol linkage; B = somatostatin peptide or fragment that binds to somatostatin receptor).

L15 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2000:628157 CAPLUS
DOCUMENT NUMBER: 133:219807

TITLE: Kit for radiolabeling proteins with yttrium-90
INVENTOR(S): **Chinn, Paul**
PATENT ASSIGNEE(S): Idec Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000052031	A2	20000908	WO 2000-US5078	20000229
WO 2000052031	A3	20010301		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2362908	AA	20000908	CA 2000-2362908	20000229
NZ 513667	A	20010928	NZ 2000-513667	20000229
EP 1156835	A2	20011128	EP 2000-919345	20000229
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008635	A	20011226	BR 2000-8635	20000229
EE 200100461	A	20021015	EE 2001-461	20000229
JP 2002538164	T2	20021112	JP 2000-602256	20000229
RU 2221807	C2	20040120	RU 2001-126396	20000229
AU 780311	B2	20050317	AU 2000-40046	20000229
US 6994840	B1	20060207	US 2000-628186	20000728
ZA 2001006945	A	20021122	ZA 2001-6945	20010822
BG 105853	A	20020628	BG 2001-105853	20010829
NO 2001004239	A	20011101	NO 2001-4239	20010831
HR 2001000713	A1	20021231	HR 2001-713	20011001
US 2006067884	A1	20060330	US 2005-181811	20050715

PRIORITY APPLN. INFO.:	US 1999-259338	A	19990301
	WO 2000-US5078	W	20000229
	US 2000-628186	A1	20000728

ED Entered STN: 10 Sep 2000
AB Methods and kits for radiolabeling proteins and peptides with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification Such kits and methods will be particularly useful in bringing radioimmunotherapy to the hospital and outpatient setting for the treatment of cancer.

L15 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 1991:499410 CAPLUS
DOCUMENT NUMBER: 115:99410
TITLE: Anthracycline derivative conjugates having a novel linker, methods for their production, and their use as cytotoxic agents for targeting therapy
INVENTOR(S): Greenfield, Robert S.; **Braslawsky, Gary R.**; Olech, Lee J.; Kaneko, Takushi; Kiener, Peter A.
PATENT ASSIGNEE(S): Bristol-Myers Co., USA
SOURCE: Eur. Pat. Appl., 70 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 398305	A2	19901122	EP 1990-109268	19900516
EP 398305	A3	19910320		
EP 398305	B1	19970319		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5122368	A	19920616	US 1989-353729	19890517
CA 2016584	AA	19901117	CA 1990-2016584	19900511
CA 2016584	C	19990629		
IL 94379	A1	19970218	IL 1990-94379	19900514
FI 102356	B1	19981130	FI 1990-2387	19900514
NO 9002197	A	19901119	NO 1990-2197	19900516
NO 300691	B1	19970707		
AU 9055117	A1	19901122	AU 1990-55117	19900516
AU 631638	B2	19921203		
ZA 9003757	A	19920129	ZA 1990-3757	19900516
AT 150321	E	19970415	AT 1990-109268	19900516
ES 2099075	T3	19970516	ES 1990-109268	19900516
JP 03027321	A2	19910205	JP 1990-125629	19900517
JP 3062696	B2	20000712		
KR 136899	B1	19980425	KR 1990-7085	19900517
PRIORITY APPLN. INFO.:			US 1989-353729 A	19890517
			US 1988-155181 B2	19880211
			US 1988-270509 B2	19881116

OTHER SOURCE(S): MARPAT 115:99410
ED Entered STN: 06 Sep 1991
AB The title conjugates are provided, as are methods for their production, pharmaceutical compns., and methods for delivering cytotoxic anthracyclines to a selected population of cells desired to be eliminated. The anthracycline conjugates comprise ≥1 anthracycline mol. linked to a ligand that is reactive with a cell population to be eliminated, the anthracycline having a keto group at the C-13 position, and being attached to the ligand via a linker arm and being bound to that linker arm via an acid-sensitive acylhydrazone bond at the 13-keto position of the anthracycline. The conjugates of the invention are therefore useful in antibody- or ligand-mediated drug delivery systems for the preferential killing of a selected cell population in the treatment of diseases such as cancers and other tumors non-cytocidal viral or other pathogenic infections, and autoimmune disorders. Thus, a cysteine-containing bombesin analog was synthesized, purified, and reacted with adriamycin 13-[3-(2-pyridyldithio)propionyl]hydrazone-HCl (I) (preparation given). Binding activity of the peptide in the bombesin-adriamycin conjugate was not disturbed, the conjugate retaining the ability to bond to bombesin receptor-pos. cells. The conjugate was highly cytotoxic toward SVT2 transformed fibroblast cells and was more potent than free adriamycin. A portion of the cytotoxic activity of the conjugate was blocked by excess bombesin. The conjugate was also specifically cytotoxic toward HCT116 colon carcinoma cells and Swiss 3T3 cells. Conjugates of adriamycin with various monoclonal antibodies, with EGF, and with transferrin are also described.

L15 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1993:641371 CAPLUS
DOCUMENT NUMBER: 119:241371

TITLE: Thioether-linked drug-ligand conjugates
INVENTOR(S): Willner, David; Trail, Pamela A.; King, Dalton H.; Hofstead, Sandra J.; Greenfield, Robert S.; **Braslawsky, Gary R.**
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: Eur. Pat. Appl., 66 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 554708	A1	19930811	EP 1993-100732	19930119
EP 554708	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5622929	A	19970422	US 1992-824951	19920123
CA 2087286	AA	19930724	CA 1993-2087286	19930114
CA 2087286	C	20040406		
AT 294592	E	20050515	AT 1993-100732	19930119
ES 2240959	T3	20051016	ES 1993-100732	19930119
AU 9331881	A1	19930729	AU 1993-31881	19930120
AU 666903	B2	19960229		
ZA 9300444	A	19930721	ZA 1993-444	19930121
NO 9300189	A	19930726	NO 1993-189	19930121
JP 06025012	A2	19940201	JP 1993-40372	19930121
HU 68345	A2	19950628	HU 1993-156	19930121
RO 112618	B1	19971128	RO 1993-69	19930121
PL 172718	B1	19971128	PL 1993-317516	19930122
PL 172715	B1	19971128	PL 1993-317519	19930122
PL 172828	B1	19971231	PL 1993-297514	19930122
PL 172837	B1	19971231	PL 1993-317517	19930122
PL 172827	B1	19971231	PL 1993-317518	19930122
PL 172824	B1	19971231	PL 1993-317715	19930122
CN 1074684	A	19930728	CN 1993-100709	19930123
CN 1040540	B	19981104		
US 5606017	A	19970225	US 1995-468162	19950606
US 5708146	A	19980113	US 1995-469840	19950606
CN 1207946	A	19990217	CN 1997-117785	19970826
CN 1180711	A	19980506	CN 1997-117908	19970829

PRIORITY APPLN. INFO.: US 1992-824951 A 19920123
OTHER SOURCE(S): MARPAT 119:241371
ED Entered STN: 11 Dec 1993
AB Drug-ligand conjugates [D=NNHCO(CH2)nAS((CH2)pC(=Y)NH)z]qX (D = drug; n = 1-10; p = 1-6; Y = O, NH2+Cl-; z = 0, 1; q = 1-10; X = ligand; A = Michael addition adduct) are prepared for therapeutic use. Adriamycin hydrochloride was reacted with maleimidocaproyl hydrazide (preparation given) and then conjugated with thiolated monoclonal antibodies (MAbs), reduced MAbs, or modified bombesin [(Cys0, Lys3)bombesin]. The conjugates had antitumor activity in mice.

L15 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1992:610646 CAPLUS
DOCUMENT NUMBER: 117:210646
TITLE: GM-CSF-inhibiting oligopeptides
INVENTOR(S): Bursuker, Isia; Greenfield, Robert S.; **Braslawsky, Gary R.**
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 499162	A2	19920819	EP 1992-102105	19920207
EP 499162	A3	19930407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
CA 2060699	AA	19920812	CA 1992-2060699	19920205
JP 05239093	A2	19930917	JP 1992-65472	19920206
PRIORITY APPLN. INFO.:			US 1991-653427 A	19910211

ED Entered STN: 28 Nov 1992
AB Oligopeptides (sequences included) are provided which can inhibit the biol. activity of GM-CSF. The oligopeptides are useful for alleviating undesirable biol. effects mediated by GM-CSF. In particular, the oligopeptides are useful for inhibiting the growth of a GM-CSF-dependent neoplastic disease. Also provided are formulations and methods for using the oligopeptides. Murine GM-CSF-derived peptide Asp-Asp-Met-Pro-Val-Thr-Leu-Asn-Glu-Glu-Val-Glu inhibited, in a dose-dependent manner, the GM-CSF-induced proliferation of HT-2 cells.

L15 ANSWER 9 OF 12 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-058133 [06] WPIX
CROSS REFERENCE: 2005-058132 [06]
DOC. NO. CPI: C2005-020196
TITLE: New composition comprising polypeptide dimers comprising at least four binding sites and at least two polypeptide chains linked via at least one interchain disulfide linkage, useful for treating e.g., cancer or autoimmune diseases.
DERWENT CLASS: B04 D16
INVENTOR(S): **CHINN, P**; GLASER, S; REFF, M; WU, X; YANG, T
PATENT ASSIGNEE(S): (BIOJ) BIOGEN IDEC MA INC
COUNTRY COUNT: 109
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2005000899	A2	20050106	(200506)*	EN	172
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2005163782	A1	20050728	(200550)		
EP 1641827	A2	20060405	(200624)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2005000899	A2		WO 2004-US20945	20040628
US 2005163782	A1	Provisional	US 2003-483877P	20030627
		Provisional	US 2003-508810P	20031003
		Provisional	US 2003-515351P	20031028
		Provisional	US 2003-516030P	20031030
			US 2004-880028	20040628
EP 1641827	A2		EP 2004-777279	20040628
			WO 2004-US20945	20040628

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1641827	A2 Based on	WO 2005000899

PRIORITY APPLN. INFO: US 2003-516030P 20031030; US
2003-483877P 20030627; US
2003-508810P 20031003; US
2003-515351P 20031028; US
2004-880028 20040628

AB WO2005000899 A UPAB: 20060410

NOVELTY - A composition comprising polypeptide dimers comprising at least four binding sites and at least two polypeptide chains, where the polypeptide chains comprise at least one heavy chain portion and a synthetic connecting **peptide**, and where greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage, is new.

DETAILED DESCRIPTION - A composition comprising polypeptide dimers comprising at least four binding sites and at least two polypeptide chains, where the polypeptide chains comprise at least one heavy chain portion and a synthetic connecting **peptide**, and where greater than about 50% of the dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage, or comprising minibody molecules comprising two polypeptide chains, where the polypeptide chains comprise a heavy chain portion and a synthetic connecting **peptide** , where the polypeptide chains lack all or part of a CH2 domain, and where greater than about 50% of the molecules are present in a form in which one of the polypeptide chains are linked via at least one interchain disulfide linkage, is new. INDEPENDENT CLAIMS are also included for:

(1) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide chain as defined above, or comprising a nucleotide sequence comprising 1857, 663, 1980, 1866, 645, 1173, or 1173 (SEQ ID NO: 17, 18, 23, 26, 27, 30 or 31, respectively) fully defined in the specification;

(2) a host cell comprising a vector; and

(3) a binding molecule comprising the amino acid sequence comprising 621, 220, 661, 621, 214, 390 or 390 (SEQ ID NO: 20, 21, 25,28, 29, 32 or 33, respectively) fully defined in the specification.

ACTIVITY - Cytostatic; Immunosuppressive; Antiinflammatory; Gastrointestinal-Gen.; Dermatological; Antiulcer; Antirheumatic; Antiarthritic; Nephrotropic; Antithyroid; Thyromimetic; Muscular-Gen.; Neuroprotective; Antianemic; CNS-Gen.; Respiratory-Gen.; Vulnerary. No biological data given.

MECHANISM OF ACTION - None given.

USE - The composition is useful for treating a subject that would benefit from treatment with an antigen binding molecule, where the subject is suffering from cancer, lymphoma, an autoimmune disease or disorder, or an inflammatory disease or disorder (claimed). The composition is useful for treating autoimmune diseases such as Crohn's disease, inflammatory bowel disease, systemic lupus erythematosus, ulcerative colitis,

rheumatoid arthritis, Goodpasture's syndrome, Grave's disease, Hashimoto's thyroiditis, pemphigus vulgaris, myasthenia gravis, scleroderma, autoimmune hemolytic anemia, pernicious anemia, Sjogren's syndrome, neurological disorders such as multiple sclerosis, and inflammatory diseases or disorders such as cystic fibrosis, sinusitis, gastroenteritis, drug reactions and burns. The polypeptide is useful for diagnostic or therapeutic purposes. The binding molecules are also useful for pretargeting applications for chemotherapeutic drug delivery. Dwg.0/35

ABEX UPTX: 20050126

ADMINISTRATION - Dosage is 1-10 mg/kg body weight administered via parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intraperitoneal, intranasal or intramuscular means.

EXAMPLE - No relevant example given.

L15 ANSWER 10 OF 12 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-058132 [06] WPIX
CROSS REFERENCE: 2005-058133 [06]
DOC. NO. CPI: C2005-020195
TITLE: New composition comprising polypeptide dimers having at least two binding sites and at least two polypeptide chains comprising a heavy chain portion and a synthetic **peptide**, useful for treating e.g., cancer or autoimmune diseases.
DERWENT CLASS: B04 D16
INVENTOR(S): **BRASLAWSKY, G**; **CHINN, P**; GLASER, S; HOPP, J; YANG, T; **BRASLAWSKY, G R**
PATENT ASSIGNEE(S): (BIOJ) BIOGEN IDEC MA INC
COUNTRY COUNT: 109
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2005000898	A2	20050106	(200506)*	EN	152
RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IT KE LS LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW					
US 2005163783	A1	20050728	(200550)		
EP 1641826	A2	20060405	(200624)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IT LI LT LU LV MC MK NL PL PT RO SE SI SK TR					

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2005000898	A2		WO 2004-US20944	20040628
US 2005163783	A1	Provisional	US 2003-483877P	20030627
		Provisional	US 2003-508810P	20031003
		Provisional	US 2003-515351P	20031028
		Provisional	US 2003-516030P	20031030
			US 2004-880320	20040628
EP 1641826	A2		EP 2004-777278	20040628
			WO 2004-US20944	20040628

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1641826	A2 Based on	WO 2005000898

PRIORITY APPLN. INFO: US 2003-516030P 20031030; US
2003-483877P 20030627; US
2003-508810P 20031003; US
2003-515351P 20031028; US
2004-880320 20040628

AB WO2005000898 A UPAB: 20060410
NOVELTY - A composition comprising polypeptide dimers having at least two binding sites and at least two polypeptide chains, where the polypeptide chains comprise at least one heavy chain portion and a synthetic connecting **peptide**, is new.

DETAILED DESCRIPTION - A composition comprising polypeptide dimers having at least two binding sites and at least two polypeptide chains, where the polypeptide chains comprise at least one heavy chain portion and a synthetic connecting **peptide** where greater than 50% of the polypeptide dimers comprise polypeptide chains that are linked via at least one interchain disulfide linkage, and where the connecting **peptide** comprises a proline residue at position 243 of the Kabat numbering system, is new.

INDEPENDENT CLAIMS are also included for:

(1) a nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide chain above, where the nucleic acid molecule comprises a nucleotide sequence comprising 1044, 1083, 1089, 1095, 1095, 1107 or 368 bp (SEQ ID NOs:16, 20,21, 38, 42, 46 or 47, respectively) fully defined in the specification, or comprising a nucleotide sequence comprising 1089 or 663 bp (SEQ ID NOs: 24 or 25, respectively) fully defined in the specification;

(2) a host cell comprising the nucleic acid molecule of (1);

(3) a connecting **peptide** comprising or consisting of the amino acid sequence selected from: Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys-Pro-Glu-Pro-Lys-Ser-Cys-Asp-Thr-Pro-Pro-Pro-Cys-Pro-Arg-Cys-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 8), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys-Pro-Glu-Pro-Lys-Ser-Cys-Asp-Thr-Pro-Pro-Pro-Cys-Pro-Arg-Cys-Pro-Arg-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 9), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 10), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys-Pro-Ala-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 11), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 12), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser-Pro-Ala-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 13), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys-Pro-Ala-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 14), Glu-Pro-Lys-Ser-Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys-Pro-Gly-Gly-Gly-Ser-Ser-Gly-Gly-Gly-Ser-Gly (SEQ ID NO: 15) and Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Cys-Pro-Glu-Pro-Lys-Ser-Cys-Asp-Thr-Pro-Pro-Pro-Cys-Pro-Arg-Cys-Pro-Ala-Pro (SEQ ID NO: 53);

(4) a domain deleted antibody molecule comprising an amino acid sequence comprising 347, 360, 362, 362, 220, 365 or 365 bp (SEQ ID NOs: 18, 22, 23, 26, 27, 40 or 44, respectively) fully defined in the specification;

(5) an antibody molecule comprising the amino acid sequence comprising 113 or 115 amino acids (SEQ ID NO: 31 or 35, respectively) fully defined in the specification;

(6) separating a first and a second polypeptide dimer where the first

polypeptide dimer comprises at least two binding sites and at least two polypeptide chains, where the polypeptide chains comprises a heavy chain portion and where the first polypeptide dimer comprises polypeptide chains that are linked via at least one disulfide linkage and where the second polypeptide dimer comprises at least two binding sites and at least two polypeptide chains, where the polypeptide chains comprises a heavy chain portion and where the second polypeptide dimer comprises polypeptide chains that are not linked via at least one disulfide linkage;

(7) separating a first properly folded antibody molecule from a second improperly folded antibody molecule, where each of the first and second antibody molecules comprises four polypeptide chains, where at least two of the chains comprise at least one heavy chain portion, and at least two of the chains comprise at least one light chain portion;

(8) increasing the amount of a first polypeptide dimer relative to the amount of a second polypeptide dimer produced by a cell, where the first and second polypeptide dimers comprise at least two binding sites and at least two polypeptide chains, the polypeptide chains comprising a heavy chain portion, where the first dimer comprises polypeptide chains that are linked via at least one disulfide linkage and where the second dimer comprises polypeptide chains that are not linked via at least one disulfide linkage;

(9) a composition comprising a first polypeptide dimer prepared by the method of (4), or comprising a first polypeptide prepared by the method of (5), or made by the method of (6);

(10) a polypeptide comprising a synthetic connecting **peptide** which comprises the amino acid sequence Cys-Pro-Glu-Pro-Lys-Ser-Cys-Asp-Thr-Pro-Pro-Pro-Cys-Pro-Arg (SEQ ID NO: 37), where the polypeptide is not a naturally occurring IgG3 molecule; and

(11) increasing the amount of dimers comprising polypeptide chains linked via at least one disulfide linkage in a population of IgG4 molecules produced by a cell.

ACTIVITY - Immunosuppressive; Antianemic; Dermatological; Muscular-Gen.; Neuroprotective; Thyromimetic; Antithyroid; Nephrotropic; Antirheumatic; Antiarthritic; Antiinflammatory; Antiulcer; Gastrointestinal-Gen. No biological data given.

MECHANISM OF ACTION - None given.

USE - The composition is useful for treating a subject that would benefit from treatment with a binding molecule, where the subject is suffering from cancer, lymphoma, an autoimmune disease or disorder, or inflammatory disease or disorder (claimed). The composition is useful for treating autoimmune diseases such as Crohn's disease, inflammatory bowel disease, systemic lupus erythematosus, ulcerative colitis, rheumatoid arthritis, Goodpasture's syndrome, Grave's disease, Hashimoto's thyroiditis, pemphigus vulgaris, myasthenia gravis, scleroderma, autoimmune hemolytic anemia, pernicious anemia, and Sjogren's syndrome. Dwg.0/35

ABEX UPTX: 20050126

ADMINISTRATION - Dosage is 1-10 mg/kg body weight administered via parenteral, topical, intravenous, oral, subcutaneous, intraarterial, intracranial, intraperitoneal, intranasal or intramuscular means.

EXAMPLE - No relevant example given.

L15 ANSWER 11 OF 12 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2002-682677 [73] WPIX
CROSS REFERENCE: 1997-108638 [10]; 1998-286601 [25]; 2001-335883 [35]; 2002-089895 [12]; 2002-154869 [20]; 2002-619209 [66]; 2003-441463 [41]
DOC. NO. CPI: C2002-192540
TITLE: Use of CD23 antagonists for inducing apoptosis in

malignant cells, or treating neoplastic disorders in a mammal, e.g. resistant Hodgkin's disease, Burkitt's lymphoma or B cell chronic lymphocytic leukemia.

DERWENT CLASS: B02 B04 D16 K08

INVENTOR(S): **BRASLAWSKY, G R**; HANNA, N; HARIHARAN, K; PATHAN, N; **BRASLAWSKY, G**

PATENT ASSIGNEE(S): (IDEC-N) IDEC PHARM CORP; (BRAS-I) BRASLAWSKY G; (HANN-I) HANNA N; (HARI-I) HARIHARAN K; (PATH-I) PATHAN N

COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2002060484	A1	20020808	(200273)*	EN	88
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW					
US 2002159996	A1	20021031	(200274)		
NO 2003003417	A	20030930	(200373)		
EP 1370292	A1	20031217	(200402)	EN	
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR					
AU 2002237972	A1	20020812	(200427)		
JP 2005503999	W	20050210	(200511)		138
ZA 2003005891	A	20050223	(200519)#		94

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002060484	A1	WO 2002-US2620	20020131
US 2002159996	A1 CIP of	US 2001-772938	20010131
		US 2001-985646	20011105
NO 2003003417	A	WO 2002-US2620	20020131
		NO 2003-3417	20030730
EP 1370292	A1	EP 2002-704280	20020131
		WO 2002-US2620	20020131
AU 2002237972	A1	AU 2002-237972	20020131
JP 2005503999	W	JP 2002-560675	20020131
		WO 2002-US2620	20020131
ZA 2003005891	A	ZA 2003-5891	20030730

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1370292	A1 Based on	WO 2002060484
AU 2002237972	A1 Based on	WO 2002060484
JP 2005503999	W Based on	WO 2002060484

PRIORITY APPLN. INFO: US 2001-985646 20011105; US 2001-772938 20010131; US 2001-855717 20010516; ZA 2003-5891 20030730

AB WO 200260484 A UPAB: 20051130

NOVELTY - Treating a neoplastic disorder in a mammal comprises

administering a CD23 antagonist to the mammal.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) inducing apoptosis (M1) in malignant cells comprising contacting the malignant cells with a CD23 antagonist; and

(2) kit useful for treating a mammal suffering from or predisposed to a neoplastic disorder comprising:

(a) at least one container having a CD23 antagonist deposited in it; and

(b) label or insert indicating that the CD23 antagonist may be used to treat the neoplastic disorder.

ACTIVITY - Cytostatic.

MECHANISM OF ACTION - CD23-Antagonist; Synergist; Inducer of Apoptosis.

Anti-CD23 antibodies were examined to determined to what extent they can induce apoptosis in malignant cells. Apoptosis was measured by a caspase-3 activation assay. Percent apoptosis was documented at 4 and 24 hours using mean fluorescent intensity in log scale (MFI). SKW cells grown in the presence of IDEC-152 (p5E8) did not show substantial activation of caspase-3 (3.8% apoptosis after 4 hours, 3.65% after 24 hours). However, cross-linking IDEC-152 and Rituxan on the SKW cell surface resulted in increased activation of caspase-3 (80.26% and 78.5% apoptosis after 4 hours, 60.51% and 66.49% after 24 hours). By comparison, cultures added with the isotype matched control antibody (CE9.1) of irrelevant specificity did not show any apoptosis. Thus, the results showed that IDEC-152 mediated antibody-dependent cell-mediated cytotoxicity (ADCC) activity of tumor cells, and induced apoptosis in CD23+ tumor cells.

USE - The method is useful for treating a neoplastic disorder in a mammal, or inducing apoptosis in malignant cells (claimed). The neoplastic disorder includes relapsed Hodgkin's disease; resistant Hodgkin's disease; high grade, low grade and intermediate grade non-Hodgkin's lymphomas; lymphoplasmacytoid lymphoma (LPL); mantle cell lymphoma (MCL); follicular lymphoma (FL); diffuse large cell lymphoma (DLCL); Burkitt's lymphoma (BL); AIDS-related lymphomas; monocytic B cell lymphoma; angioimmunoblastic lymphoadenopathy; small lymphocytic; follicular, diffuse large cell; diffuse small cleaved cell; large cell immunoblastic lymphoblastoma; small, non-cleaved; Burkitt's or non-Burkitt's; follicular, predominantly large cell; follicular, predominantly small cleaved cell; follicular, mixed small and large cell lymphomas; or particularly B cell chronic lymphocytic leukemia (B-CLL) (claimed). Dwg.0/13

ABEX UPTX: 20021113

ADMINISTRATION - Dosage is 0.05-100, preferably 0.5-10, mg/kg body weight per day. Administration is oral, parenteral (e.g. intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, rectal or vaginal), by inhalation or topical. The CD23 antagonist and chemotherapeutic agent (preferably an antibody) may be administered in any order or concurrently.

L15 ANSWER 12 OF 12 WPIX COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 1999-357351 [30] WPIX
DOC. NO. CPI: C1999-105653
TITLE: New immunogenic compositions for treating cancer or virus or parasite infection.
DERWENT CLASS: A96 B04 D16
INVENTOR(S): **BRASLAWSKY, G R**; HANNA, N; HARIHARAN, K; HARIHARA, K
PATENT ASSIGNEE(S): (IDEC-N) IDEC PHARM CORP; (BIOG-N) BIOGEN IDEC INC; (BIOJ) BIOGEN IDEC INC
COUNTRY COUNT: 84

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9913912	A1	19990325	(199930)*	EN	41
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW					
ZA 9808461	A	19990630	(199931)		36
AU 9895658	A	19990405	(199933)		
EP 1015031	A1	20000705	(200035)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					
NO 2000001413	A	20000518	(200035)		
CN 1279616	A	20010110	(200128)		
US 2001018054	A1	20010830	(200151)		
US 2001019715	A1	20010906	(200154)		
KR 2001024109	A	20010326	(200161)		
JP 2001516727	W	20011002	(200172)		32
AU 742216	B	20011220	(200208)		
RU 2219947	C2	20031227	(200413)		
US 2004137014	A1	20040715	(200447)		
US 6998125	B2	20060214	(200613)		

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 9913912	A1		WO 1998-US18495	19980917
ZA 9808461	A		ZA 1998-8461	19980916
AU 9895658	A		AU 1998-95658	19980917
EP 1015031	A1		EP 1998-949313	19980917
			WO 1998-US18495	19980917
NO 2000001413	A		WO 1998-US18495	19980917
			NO 2000-1413	20000317
CN 1279616	A		CN 1998-811280	19980917
US 2001018054	A1	Cont of	US 1997-933359	19970918
			US 2001-853580	20010514
US 2001019715	A1	Div ex	US 1997-933359	19970918
			US 2001-853581	20010514
KR 2001024109	A		KR 2000-702864	20000317
JP 2001516727	W		WO 1998-US18495	19980917
			JP 2000-511527	19980917
AU 742216	B		AU 1998-95658	19980917
RU 2219947	C2		WO 1998-US18495	19980917
			RU 2000-109595	19980917
US 2004137014	A1	Div ex	US 1997-933359	19970918
		Div ex	US 2001-853581	20010514
			US 2003-743739	20031224
US 6998125	B2	Div ex	US 1997-933359	19970918
			US 2001-853581	20010514

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9895658	A	Based on	WO 9913912
EP 1015031	A1	Based on	WO 9913912

JP 2001516727	W	Based on	WO 9913912
AU 742216	B	Previous Publ.	AU 9895658
		Based on	WO 9913912
RU 2219947	C2	Based on	WO 9913912

PRIORITY APPLN. INFO: US 1997-933359 19970918; US
2001-853580 20010514; US
2001-853581 20010514; US
2003-743739 20031224

AB WO 9913912 A UPAB: 19990802
NOVELTY - New immunogenic compositions for treating cancer or virus or parasite infection comprise a combination of antigen formulation and an agent capable of neutralizing or down-regulating immunosuppressive factors.

DETAILED DESCRIPTION - A composition (A) comprises:

(a) an admixture comprising a cancer, viral or parasitic antigen expressed by cancer, virally or parasitic infected cells and a microfluidized antigen formulation (MAF) (formulated as a stable oil-in-water emulsion), the antigen formulation comprising:

(i) a stabilizing detergent;

(ii) a micelle-forming agent; and

(iii) a biodegradable and biocompatible oil; and

(b) at least one agent which is capable of neutralizing or down-regulating the activity of immunosuppressive factors.

INDEPENDENT CLAIMS are also included for the following:

(1) a method of treatment which includes the induction of a cytotoxic T-lymphocyte (CTL) response where the improvement comprises:

(a) the administration of an adjuvant which induces a CTL response; and

(b) the administration of an antagonist of an immunosuppressive factor, where the administration of adjuvant and antagonist is effected sequentially or concurrently, and in any order;

(2) a method of restoring or boosting hematopoiesis comprising administering to a patient:

(a) an admixture as in (A) (a) which is administered to the patient to induce a CTL response in the patient which is specific for the viral or cancer antigen contained in the admixture; and

(b) at least one agent which is capable of neutralizing or down regulating the activity of tumor and host secreted immunosuppressive factors, where the admixture and the agent are administered separately or in combination, and in any order;

(3) a composition comprising an admixture as in (A) (a) and one or more transforming growth factor (TGF) beta antagonists;

(4) treatment of neoplastic or cancerous growths, comprising:

(a) administration of an admixture comprising a cancer or tumor antigen expressed by the cancer cells and a MAF (described above); and

(b) administration of at least one agent which is capable of neutralizing or down-regulating the activity of tumors and host secreted immunosuppressive factors. The admixture is administered in an amount sufficient to induce a cytotoxic T-lymphocyte response in the patient which is specific for the cancer or tumor antigen contained in the admixture.

ACTIVITY - Antitumor; Antiviral; Antiparasitic.

MECHANISM OF ACTION - Induction of a cytotoxic T-lymphocyte response.

USE - The methods can be used for restoring or boosting hematopoiesis (claimed). They can be used for treating cancers, e.g. breast cancer, brain cancer, cervical cancer, leukemia, lymphoma, prostate cancer, skin cancer, bladder cancer, kidney cancer, myeloma, colorectal cancer, or endometrial cancer, viral infections e.g. papillomavirus, hepatitis, herpes, cytomegalovirus, respiratory syncytial virus or HIV, or parasitic

infection, e.g. malaria (claimed). The agent which is capable of neutralizing or down-regulating the activity of immunosuppressive factors enhances the efficacy of tumor/viral vaccines.

ADVANTAGE - The combinations of the antigen compositions and antagonists of immunosuppressive agents results in a synergistic enhancement of CTL response, thereby resulting in enhanced therapeutic response against targeted antigen-expressing cells.

Dwg.0/4

ABEX UPTX: 19990802

ADMINSTRATION - Administration of the adjuvant is especially intradermal, intramuscular or subcutaneous. Administration of the TGF antagonist is especially intravenous.

EXAMPLE - Mice were inoculated with ovalbumin expressing EG7 cells (2 x 10 to the power 6 cells/mouse). On day 7, post-inoculation mice bearing 250-350 mm3 size tumors were sorted into groups. Group A, the control group received no antigen injection. Group B received 30 microg of ovalbumin in PROVAX (RTM) s.c. Group C received 30 microg of ovalbumin in PROVAX (RTM) s.c. and 50 microg of anti-transforming growth factor beta (TGF-beta) antibodies i.p. Per mouse. Group D received 50 microg of anti-TGF beta antibodies i.p.

The results showed that the treatment of mice bearing progressively growing EG7 tumors with anti-TGF-beta antibodies in conjunction with ovalbumin in PROVAX gave enhanced anti-tumor activity under conditions where treatment with ovalbumin-PROVAX (RTM) is not effective.

```
=> d his full

     (FILE 'HOME' ENTERED AT 16:01:15 ON 06 JUN 2006)

     FILE 'REGISTRY' ENTERED AT 16:01:20 ON 06 JUN 2006
L1             6 SEA ABB=ON  PLU=ON  YCYYCFWKTCT|CYYYCFWKTCT|YYCYCFWKTCT/SQSP

     FILE 'CAPLUS' ENTERED AT 16:02:47 ON 06 JUN 2006
L2             1 SEA ABB=ON  PLU=ON  L1
                 D AU
                 E BRASLAWSKY G/AU
                 E CHINN P/AU

     FILE 'REGISTRY' ENTERED AT 16:04:18 ON 06 JUN 2006
                 D QUE L1
                 D L1 RN CN SQL KWIC NTE
                 D L1 RN CN SQL KWIC NTE 2-6

     FILE 'CAPLUS' ENTERED AT 16:07:50 ON 06 JUN 2006
                 D QUE L2
                 D IBIB ED AB HITRN
                 D SCAN L2
L3            41 SEA ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L4            21 SEA ABB=ON  PLU=ON  CHINN P?/AU
L5             5 SEA ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDES/CW

     FILE 'MEDLINE' ENTERED AT 16:20:49 ON 06 JUN 2006
L6            35 SEA ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L7            92 SEA ABB=ON  PLU=ON  CHINN P?/AU
L8             3 SEA ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?
                 D TRIAL 1-3

     FILE 'EMBASE' ENTERED AT 16:21:24 ON 06 JUN 2006
L9            25 SEA ABB=ON  PLU=ON  BRASLAWSKY G?/AU
L10           18 SEA ABB=ON  PLU=ON  CHINN P?/AU
L11            1 SEA ABB=ON  PLU=ON  L3 AND L4
L12            2 SEA ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?

     FILE 'BIOSIS' ENTERED AT 16:25:01 ON 06 JUN 2006
L13            2 SEA ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?

     FILE 'WPIX' ENTERED AT 16:25:15 ON 06 JUN 2006
L14            7 SEA ABB=ON  PLU=ON  (L3 OR L4) AND PEPTIDE?

     FILE 'CAPLUS' ENTERED AT 16:26:43 ON 06 JUN 2006
                 D QUE L5

     FILE 'MEDLINE' ENTERED AT 16:27:01 ON 06 JUN 2006
                 D QUE L8

     FILE 'EMBASE' ENTERED AT 16:27:08 ON 06 JUN 2006
                 D QUE L12

     FILE 'BIOSIS' ENTERED AT 16:27:15 ON 06 JUN 2006
                 D QUE L13

     FILE 'WPIX' ENTERED AT 16:27:21 ON 06 JUN 2006
                 D QUE L14
```

FILE 'MEDLINE, CAPLUS, EMBASE, BIOSIS, WPIX' ENTERED AT 16:27:36 ON 06 JUN 2006

L15 12 DUP REM L8 L5 L12 L13 L14 (7 DUPLICATES REMOVED)
ANSWERS '1-3' FROM FILE MEDLINE
ANSWERS '4-8' FROM FILE CAPLUS
ANSWERS '9-12' FROM FILE WPIX
D IBIB ED AB L15 1-8
D IBIB AB ABEX L15 9-12

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUN 2006 HIGHEST RN 886840-90-0
DICTIONARY FILE UPDATES: 5 JUN 2006 HIGHEST RN 886840-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE CAPLUS

FILE COVERS 1907 - 6 Jun 2006 VOL 144 ISS 24
FILE LAST UPDATED: 5 Jun 2006 (20060605/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

FILE MEDLINE
FILE LAST UPDATED: 3 JUN 2006 (20060603/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE
FILE COVERS 1974 TO 6 Jun 2006 (20060606/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 31 May 2006 (20060531/ED)

FILE WPIX
FILE LAST UPDATED: 2 JUN 2006 <20060602/UP>
MOST RECENT DERWENT UPDATE: 200635 <200635/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and

http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

=>